|D012141||Respiratory Tract Infections NIH||0.16|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
180 people from the medical staff and high-risk people in Baqiyatallah Hospital, who are in close contact with patients, will enter the study. Participants will be divided into two intervention groups and one control group. The control group will use the full protective equipment assigned to the treatment staff. In addition to protective equipment, the first intervention team will receive a daily diet of 200 mg hydroxychloroquine tablets. The second intervention team, while observing and using the complete protective equipment, will place a thin layer of Mucodentol gel in the vestibular area of the mouth daily, every 6 to 8 hours. At the beginning of the treatment, qualified people will participate in the study while recording demographic and clinical information, PCR test will be performed, and if they have negative PCR, they will be in one of the 3 study groups. During the study, if the symptoms of the disease occur in each of the participants, the test will be taken again. If the test is positive, the person will withdraw from the study, and the patient's information will be recorded. Finally, the people present in the study will be tested for PCR, and the results of the disease and the side effects of the drugs will be compared.
Description: Laboratory PCR testing can help diagnose the diseaseMeasure: PCR test Time: up to 1 month
Description: Normal blood cell count and CRP count (normal laboratory range)Measure: Laboratory Treatment Response Time: up to 1 month
Description: Complications in both groups should be evaluated and evaluated during treatment.Measure: drug reactions Adverse Time: up to 1 month
Description: There will be known allergic reactions to the drugs.Measure: Allergic drug Time: up to 1 month
Description: CT scans help determine how much the lungs are affected by COVID-19.Measure: Radiological Treatment Response Time: up to 1 month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports